<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This study was aimed to investigate the value of CD58 in evaluation of early therapeutic effect on childhood <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The expression features of CD58 in 135 cases of childhood <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> were analyzed by four-color flow cytometry; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> detection protocol for <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> using CD58/CD10/CD34/CD19 combination was established; the correlation between the expression features of CD58 and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> detection was analyzed for the early therapeutic response in childhood <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The results showed that the mean value of CD58 MFI in 135 cases of <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> was 113.08 +/- 63.33, which was significantly higher than that in 15 cases of <z:mpath ids='MPATH_458'>normal</z:mpath> bone marrow controls (14.68 +/- 5.26, P &lt; 0.01) </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, CD58 was over expressed in 51.9% (70/135) of <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> patients, indicating that CD58 could be an effective marker in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> detection </plain></SENT>
<SENT sid="4" pm="."><plain>The CD58/CD10/CD34/CD19 was the second most effective combination next to TdT/CD10/CD34/CD19 in <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> detection with flow cytometry </plain></SENT>
<SENT sid="5" pm="."><plain>Meanwhile, the positive rate of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> detection by flow cytometry was significantly lower in CD58 over expression group (P &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>It is concluded that CD58 may be used as an indicator for detection of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> in <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> patients, which would enrich the combination of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> detection </plain></SENT>
<SENT sid="7" pm="."><plain>The CD58 over expression may be considered as a marker of a favorable prognosis in childhood <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> </plain></SENT>
</text></document>